Malaria Vaccine Proves Effective in Clinical Trial















Share on Tumblr



Image: CDC

  • What a Plant Knows

    How does a Venus flytrap know when to snap shut? Can it actually feel an insect’s tiny, spindly legs? And how do cherry blossoms know when to bloom? Can they...

    Read More »

A new vaccine stimulated human immune cells to recognize and kill malaria parasites in a recent clinical trial. The vaccine proved effective in both infected human blood samples and mice whose immune systems had been modified to mimic that of humans.

"This is the first malaria vaccine clinical trial to clearly demonstrate antiparasitic activity by vaccine-induced antibodies," writes Pierre Druilhe of the Pasteur Institute in Paris, who led the study. Malaria--a parasite carried by certain mosquitoes--sickens more than 300 million people worldwide every year and causes at least one million deaths, primarily of young children, according to the World Health Organization. Vaccine development has been hindered by the microscopic parasites adaptability and complexity.

Druilhe and his colleagues focused on a malaria protein--merozoite surface protein 3 (MSP-3)--that prior research had identified as the focus of the immune systems of adults who had proven resistant to the disease. When paired with monocytes (a type of white blood cell), antibodies to MSP-3had cleared a blood sample of the parasite.

In the new work, described in a report published online yesterday by the Public Library of Science,the team injected an MSP-3-based vaccine into 30 European volunteers who had never had malaria, readministering it after one month and again after four months. Blood samples were taken one month after each injection. These blood samples were then compared to French blood samples from individuals with no immunity to malaria and African blood samples from people with immunity.

Nearly every vaccinated sample produced an immune response to malaria when it was introduced in vitro and 77 percent produced anti-MSP-3 antibodies. Plus, these antibodies proved to be as good at killing the parasite as those from immune adults and, in some cases, better, destroying up to twice as much. "This type of immune response, characteristic of immune adults living in malaria-endemic regions, requires under natural conditions 10 to 15 years of daily exposure to billions of infected red blood cells," Druilhe notes.

Due to ethical concerns, the volunteers themselves were not exposed to malaria to test the vaccine's efficacy. But the scientists did conduct in vivo experiments in mice, infecting them with the parasite and then injecting a small amount of the vaccine-produced antibodies. The antibodies significantly cut the number of parasites in the blood of these animals and in some cases wiped it out entirely--outperforming even the immune systems of naturally resistant humans.

The vaccine also showed long-lasting promise, with blood from some of the immunized individuals showing strong resistance a year later. Thus encouraged, Druilhe and his fellow scientists have begun a study of the vaccine's ability to fight the parasite in a larger group of people already suffering from malaria.



1 Comments

Add Comment
View
  1. 1. Carlton22 11:39 AM 4/27/09

    Great work but what if its not needed? What if the profit motive was removed? Would we also find that "cures" for cancer already exist and have been blocked by the "Mainstream"? I think so!

    Jim Humble has already found a "cure" for Malaria, Aids and just about every disease facing the African Nations and the world including influenza. But will medical authorities listen or are they more interested in profit than in saving lives? Try this yourself. Make a 28% solution of Sodium Chlorite (NaCl02), Jim calls it his Miracle Mineral Solution. Mix 15 drops of the solution with 1 teaspoon of either pure lemon or lime juice, or acetic acid, or 5% vinnegar and let it set for 3 minutes. This makes Chlorine Dioxide (Cl02), the most powerful killer of pathogens known to man. Now add 4 ounces of water or pure apple juice (no vitamin C added). Drink it down. Jim did this with thousands of Africans suffering with Malaria, Aids, etc., etc., it didn't matter what they were suffereing from, and got a 100% cure rate. It even drove worms out of their bodies. In many instances they did before and after blood tests to select for those who definitely did have malaria. And still, 100% cured. All this for pennies a dose. It usually took only one dose, in a very few cases, a follow-up dose was given the next day. Chlorine dioxide treats water and sewage systems just as effectively and is much safer to use than chlorine alone. Chlorine combines to make many known carcinogens. Chlorine dioxide eliminates the pathogen then changes to salt and water.

    Did Jim get the Noble Prize for this solution to almost every disease of man? Nope. Jim is living in hiding somewhere in Mexico or ??? The World Health Organization refused to study this for years and then gave a cursory decision that it didn't work. What science is that? If the FDA and Big Pharma can't make their blood money from drugs that do not cure but only treat symptoms, they are not interested except to go after and destroy those that dare to actually put forth a cure. They make it impossibly expensive to get the testing done that is needed, or they do not follow the proper protocol and get "doctored" (pardon the pun) results. Go figure.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Email this Article

Malaria Vaccine Proves Effective in Clinical Trial

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X